Baxalta Announces Opening of Global Innovation Center Dedicated to Pioneering Breakthroughs for Patients with Unmet Needs

  • Global Innovation Center, based in Cambridge, Mass., serves as headquarters for Research & Development (R&D), Oncology, Biosimilars and Business Development
  • Cambridge life science community provides Baxalta with access to a range of talent, innovation and collaboration partners with complementary expertise
  • Baxalta is committed to further establishing itself as a leading development powerhouse with a focus on expanding its pipeline in rare and underserved diseases through external innovation

BANNOCKBURN, Ill.--()--Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced the official opening of its Global Innovation Center in Cambridge, Massachusetts. The Center is located in Kendall Square at 650 East Kendall Street and will act as the innovation hub of the company's global infrastructure designed to effectively deliver advanced treatments to patients.

"We are honored to join this robust biotech community in Cambridge," said John Orloff, M.D., head of Research & Development and chief scientific officer, Baxalta. "Kendall Square was a natural choice for the location of our Global Innovation Center. Here we are surrounded by some of the top minds in the industry, immersed in a biotech community that is unparalleled by any other in the world. Our goal is to become a leading development powerhouse to deliver innovative treatments for patients with unmet medical needs."

Baxalta's innovation efforts are focused on the development of lifesaving therapies in hematology, immunology and oncology. The company's approach to expanding its pipeline is based on an external innovation model, sourcing compounds externally through in-licensing or acquisitions. The Cambridge life science community will provide Baxalta access to a range of innovations and collaboration partners with complementary expertise to advance new treatments for patients.

Baxalta has approximately 40 programs in development, and plans to launch 20 new products by 2020, leveraging its experienced leadership team, existing global capabilities and footprint in more than 100 countries.

"Massachusetts is home to an extensive community of top-tier academic institutions, research facilities and life-science companies," said Governor Charlie Baker. "The biotechnology cluster is an important part of our life-science community and a key driver for our economy. We remain committed to the life-sciences and welcome Baxalta to the Commonwealth."

The Center supports cross-functional, co-located teams including R&D, Oncology, Biosimilars, Business Development, Corporate Strategy and Customer Operations, along with others that support or work closely with R&D. By the end of 2015, Baxalta expects to employ approximately 500 individuals at the Global Innovation Center. In addition, the company also operates a hemophilia treatment manufacturing facility in Milford, Massachusetts.

About Baxalta

Baxalta Incorporated (NYSE: BXLT) is a $6 billion global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Driven by passion to make a meaningful impact on patients' lives, Baxalta's broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy. The Baxalta Global Innovation and R&D Center is located in Cambridge, Massachusetts. Launched in 2015 following separation from Baxter International, Baxalta's heritage in biopharmaceuticals spans decades. Baxalta's therapies are available in more than 100 countries and it has advanced biological manufacturing operations across 12 facilities, including state-of-the-art recombinant production and plasma fractionation. Headquartered in Northern Illinois, Baxalta employs 16,000 employees worldwide.

Forward-Looking Statements

This release includes forward-looking statements related to its R&D pipeline programs as well as future plans for its Cambridge facilities including headcount. Such statements are made of the date that they were first issued and are based on current expectations, beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Baxalta's control and which could cause actual results to differ materially from those in the forward-looking statements, including the following: clinical trial results; satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; product quality, manufacturing or supply issues; patient safety issues; demand for and market acceptance of risks for new and existing products; pricing, reimbursement, taxation and rebate policies of government agencies and private payers; the impact of competitive products and pricing; accurate identification of and execution on business development and R&D opportunities and realization of anticipated benefits; loss of key employees or inability to identify and recruit new employees; the adequacy of Baxalta's cash flows from operations to meet its ongoing cash obligations and fund its investment program; and other risks identified in Baxalta's filings with the Securities and Exchange Commission, all of which are available on Baxalta's website. Baxalta expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.



Baxalta Media Relations
Albert Liao, +1-617-834-9285
[email protected]
Sara Noonan, +1-617-417-856
[email protected]
Baxalta Investor Relations
Mary Kay Ladone, +1-224-948-3371
[email protected]
Lorna Williams, +1-224-948-3511
[email protected]